← FDA Drug Approvals (Drugs@FDA)

GLYXAMBI

NDA · New Drug Application · Sponsor: BOEHRINGER INGELHEIM · Approved 2015-01-30

Drug application

FDA Application #

NDA206073

Application type

New Drug Application

Brand name

GLYXAMBI

Generic name

EMPAGLIFLOZIN AND LINAGLIPTIN

Active ingredients

EMPAGLIFLOZIN; LINAGLIPTIN

Dosage form

TABLET

Route

ORAL

Marketing status

Prescription

Sponsor

BOEHRINGER INGELHEIM

Manufacturer

Boehringer Ingelheim Pharmaceuticals, Inc.

First approval

2015-01-30

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown